+233.2%
MA vs MRNA
+786.4%
-553.1%
-41.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -2.2% | +2.0% | -0.1% |
| 7D | -5.4% | -12.7% | +7.3% | -5.1% |
| 30D | +0.5% | -20.7% | +21.1% | +0.9% |
| 3M | +9.2% | +46.3% | -37.1% | +8.2% |
| 6M | +26.0% | +305.2% | -279.2% | +19.8% |
| YTD | +10.3% | +561.2% | -551.0% | +2.6% |
| 1Y | +19.3% | +772.1% | -752.8% | +9.8% |
| 3Y | +57.5% | +147.0% | -89.5% | +48.9% |
| 5Y | +89.7% | -26.1% | +115.8% | +80.6% |
| All | +233.2% | +786.4% | -553.1% | +200.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling